# Basket Study for Oligo-metastatic Breast Cancer

> **NCT05982678** · PHASE2 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 72 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT05982678
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-02
- **Primary completion:** 2027-10-01
- **Final completion:** 2034-10-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05982678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05982678, "Basket Study for Oligo-metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05982678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*